Last reviewed · How we verify
NCT04785885: ACTPOC
Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery
trial testing iStat Handheld Blood Analyzer in Transcatheter Aortic Valve Replacement in 40 participants. Status unknown.
31 March 2022
Quick facts
| Lead sponsor | Rhode Island Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 9 March 2021 |
| Primary completion | 31 March 2022 |
| Estimated completion | 30 April 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- iStat Handheld Blood Analyzer
- Hemochron
Conditions studied
- Transcatheter Aortic Valve Replacement — all drugs for Transcatheter Aortic Valve Replacement →
- Cardiac Valve Annuloplasty — all drugs for Cardiac Valve Annuloplasty →
Sponsor
Rhode Island Hospital
Who can join
Adults 18 to 90, any sex, with Transcatheter Aortic Valve Replacement or Cardiac Valve Annuloplasty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The efficiency and promptness of heparin anticoagulation is necessary during the structural heart procedures to minimize time from insertion of cannulae to valve deployment in cardiac surgery. The goal of this study is to determine how rapidly the adequacy of heparin induced anticoagulation occurs using two different point of care activated clotting time technologies (iSTAT and Hemochron).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04785885
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transcatheter Aortic Valve Replacement
Currently open trials in the same condition.
- NCT06559332 — Coronary Artery Disease Assessment Strategies in TAVI Patients · NA · recruiting
- NCT06896227 — TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics · NA · recruiting
- NCT06420830 — Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis. · recruiting
- NCT05758701 — CT TAVR Abdomen Study · Phase 4 · recruiting
- NCT06000943 — Ischemic And Bleeding Risk Assessment After TAVR · recruiting
Other Rhode Island Hospital trials
Trials by the same sponsor.
- NCT06747221 — Implementation Science to Enhance HIV Testing Services During Emergency Care in Kenya · NA · not yet recruiting
- NCT07211087 — Improving the Treatment of Depression Among Youth With HIV · NA · not yet recruiting
- NCT06754527 — Options for Navigating Talking About Risk and Adolescent Choices · NA · not yet recruiting
- NCT07144631 — Peroneal Electrical Nerve Stimulation in Pregnancy for Restless Legs Syndrome · NA · recruiting
- NCT06942455 — A Sleep Hygiene Intervention to Improve Sleep Health in Urban, Latino Middle School Children · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04785885 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rhode Island Hospital
- Last refreshed: 29 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04785885.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing